Coripharma is a European pharmaceutical company, built on solid heritage. Our experienced team offers out-licensing and contract manufacturing services to pharmaceutical companies. Coripharma specializes in generic pharmaceutical products, solid oral dosage forms.

Coripharma

Coripharma proudly announces the completion of the 16th dossier from its own development, marking a significant milestone in the company’s journey of innovation and excellence.

Lisdexamphetamine is based on the reference product Elvanse®, commonly prescribed for managing attention deficit disorder (ADHD).

This achievement is a testament to the outstanding efforts of the R&D team and the seamless collaboration within Coripharma. The timing couldn’t be better, as the secured DCP slot in January 2025 strategically positions our partners for successful market entry.

With this milestone, Coripharma reaffirms its dedication to development of high-quality generics and strengthens its global partnerships.

Coripharma Completes Lisdexamphetamine Dossier, Secures DCP Slot for January 2025

Margret has extensive experience in the pharmaceutical Industry having worked as the Quality Manager of Florealis and prior to that being a Qualified Person at Actavis.

Margret holds a PhD in Medical Life Science from the University of Iceland as well as a master’s degree in pharmacology.

“It is very exciting to get the opportunity to lead the Quality operations at Coripharma. I look forward to continuing working with the quality team to strengthen our quality management system to ensure that we remain competitive and responsive so we can meet customers’ requirements and regulatory standards”.

Dr. Margret Bessadottir

“At Coripharma we are fortunate to have a great group of people working with us and to have the opportunity to promote within. Margret has been a strong part of our team, leading the Quality Control department in the past, now stepping up to head our Quality Operations. It’s imperative to a company like ours to maintain the highest standard of quality in all aspects and I’m confident that Margret is exactly the right person to oversee that.”

Jonina Gudmundsdottir

Coripharma is a pharmaceutical company that specializes in development, manufacturing, and exporting of generic pharmaceuticals. Coripharma employs around 190 people.

Dr. Margret Bessadottir has been appointed Director of Quality Operations at Coripharma and will be joining the Executive Management Team.

Dr. Margret Bessadottir appointed to the role of Director of Quality Operations at Coripharma

Bio Equivalence studies for Ruxolitinib have passed successfully and we believe Coripharma is among the front runners in developing the generic product. The dossier is set to be completed in Q1 2024, pending stability studies.

The progress of development has been excellent, and we are thankful for our great team and their superb efforts. 

If you want to join our journey, please reach out to our commercial team.

Ruxolitinib is indicated to treat Myelofibrosis and is based on the reference product Jakavi®.

Ruxolitinib development in final stages. Dossier availability in Q1 2024, with DCP slots in April

Based on the reference product ISENTRESS®  Film-coated tablets, this product is indicated for treatment of HIV infections.

The successful pivotal BE study of Raltegravir is a great achievement in development and it’s safe to say the this is a major success story for our R&D team and Coripharma in general.

We expect to have the dossier available in Q1 2023 and our business development team remains available to discuss opportunities with our customers.

Raltegravir 600mg Film-coated tablets has passed its pivotal bioequivalence study.

Coripharma announces successful pivotal BE study of Raltegravir 600mg

About us

Services

Sustainability

Careers

Coripharma announces successful pivotal BE study of Raltegravir 600mg

More news

Coripharma Completes Lisdexamphetamine Dossier, Secures DCP Slot for January 2025

Dr. Margret Bessadottir appointed to the role of Director of Quality Operations at Coripharma

Ruxolitinib development in final stages. Dossier availability in Q1 2024, with DCP slots in April

+354 4206700